We are a clinical-stage company developing therapeutic antibodies for inhibitory receptors on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases
Our lead drug candidate is antolimab (AK002), an investigational antibody that targets Siglec-8, an inhibitory receptor selectively found on mast cells and eosinophils. In clinical and preclinical studies, antolimab has been shown to broadly inhibit mast cells and rapidly deplete eosinophils.
Our most advanced clinical programs are in eosinophilic gastrointestinal diseases (EGIDs), inflammatory diseases characterized by persistent gastrointestinal symptoms with elevated eosinophils and mast cells in the esophagus, stomach, small intestine (duodenum) and/or colon. Antolimab has demonstrated positive clinical activity in several mast cell and eosinophil driven diseases, including in a Phase 2 randomized, double-blind, placebo-controlled study in patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Enteritis (EEn, formerly referred to as EGE). Other indications where antolimab has shown clinical activity are chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.